Covetrus, Inc. (NASDAQ:CVET) insider Dustin Finer sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, June 8th. The shares were sold at an average price of $27.86, for a total value of $41,790.00. Following the transaction, the insider now owns 36,710 shares in the company, valued at $1,022,740.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Dustin Finer also recently made the following trade(s):
- On Wednesday, June 2nd, Dustin Finer sold 2,322 shares of Covetrus stock. The shares were sold at an average price of $27.28, for a total value of $63,344.16.
- On Tuesday, May 4th, Dustin Finer sold 1,500 shares of Covetrus stock. The shares were sold at an average price of $30.43, for a total value of $45,645.00.
- On Tuesday, April 6th, Dustin Finer sold 1,500 shares of Covetrus stock. The shares were sold at an average price of $29.38, for a total value of $44,070.00.
Shares of Covetrus stock traded up $0.36 during trading on Thursday, reaching $27.83. The company’s stock had a trading volume of 285,178 shares, compared to its average volume of 754,568. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.27 and a current ratio of 2.09. The stock has a fifty day moving average price of $28.23. The company has a market cap of $3.80 billion, a price-to-earnings ratio of -349.58, a price-to-earnings-growth ratio of 1.74 and a beta of 2.05. Covetrus, Inc. has a one year low of $15.03 and a one year high of $40.78.
Several equities analysts have weighed in on CVET shares. Raymond James raised their target price on Covetrus from $31.00 to $39.00 and gave the company an “outperform” rating in a report on Tuesday, March 2nd. Zacks Investment Research upgraded Covetrus from a “sell” rating to a “hold” rating in a report on Thursday, May 20th. Finally, Barclays assumed coverage on Covetrus in a report on Wednesday, February 17th. They set an “overweight” rating and a $48.00 target price on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Covetrus has an average rating of “Buy” and a consensus target price of $33.40.
Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers.
Recommended Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.